Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the capacity in the whole genome sequencing programme for the treatment of less survivable cancers.

Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service (GMS) as directed by the National Genomic Test Directory (NGTD), which includes tests for over 7,000 rare diseases with an associated genetic cause and over 200 cancer clinical indications, including both whole genome sequencing (WGS) and non-WGS testing. The NGTD sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used.

WGS is available on the NGTD for all paediatric and central nervous system tumours where there is a clear, clinical question and where results have expected utility/impact. WGS for all other adult solid tumours, including less survivable cancers, can be performed where there is a clinical need and where results are likely to change clinical management.